Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing

Figure 4

Genomic landscape of patients exhibiting cooccurrence of FGFR2 amplification and fusion. (a) Venn diagram showing the percentage distribution of patients with FGFR2 genomic alterations, including amplification (red), fusion (sky blue), and cooccurrence of amplification and fusion (purple) (). (b, c) Numbers of patients exhibiting FGFR2 amplification, fusion, and cooccurrence of amplification and fusion and the percentage of cases with each tumor type: green, gastric cancer; magenta, sarcoma. (d) Comprehensive clinical characteristics of and the structural alterations present in patients, including tumor type, presence of amplification, presence of fusion, and FGFR2 IHC (top), age and sex (middle), and MSI, TMB, and PD-L1 status (bottom). (e) Representative immunohistochemistry results of FGFR2 showing strong cytoplasmic staining in the tumor cells. Scale bar: 100 μm and 80 μm. (f) Analysis of correlations between the PD-L1 expression level and FGFR2 aberrations in GC (, FGFR2⁺: black circles and FGFR2⁻: gray circles). (g) Alluvial diagram representing the flow from tumor types to FGFR2 alteration and disease response to chemotherapy. (h) Overall survival (OS, top) and progression-free survival (PFS, bottom) curves calculated using the Kaplan–Meier method for groups classified according to FGFR2 alteration. CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.